90
Participants
Start Date
May 10, 2017
Primary Completion Date
June 20, 2018
Study Completion Date
June 20, 2018
NI-0101
Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody targeting TLR4
Placebo
Placebo
"University Multiprofile Hospital for Active TreatmenT St. Ivan Rilski", Sofia
CRU Hungary Ltd, Miskolc
"Multi-profile Hospital for Active Treatment Trimontsium", Plovdiv
"University Multiprofile Hospital for Active Treatment Kaspela", Plovdiv
Multiprofile Hospital for Active Treatment - Shumen AD, Shumen
Institute of Rheumatology, Belgrade
"Special Hospital for Rheumatic Diseases Novi Sad", Novi Sad
"General Hospital Djordje Joanovic", Zrenjanin
Clinical Center Kragujevac, Kragujevac
Clinic for internal medicine with centre for dialysis, Mostar
ARENSIA Phase I Unit at the Research Institute of Clinical Medicine, Tbilisi
High Technology Medical Center; University clinic, Tbilisi
Emergency Cardiology Center by Acad. G.Chapidze, Tbilisi
Insitute of Clinical Cardiology, Tbilisi
Tbilisi Central Hospital, Tbilisi
Multiprofile Clinic Consilium Medulla, Tbilisi
Republican Clinical Hospital, ARENSIA Phase I unit, Chisinau
Centrum Miriada, Bialystok
Zespól Poradni Specjalistycznych REUMED, Lublin
Lead Sponsor
Light Chain Bioscience - Novimmune SA
INDUSTRY